Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Eli Lilly's Zepbound is set to dominate the global obesity market, offering new hope with its groundbreaking treatment for weight management.

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See why I remain bullish on LLY stock.

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for May 1.

Eli Lilly has caught up to Novo Nordisk, says BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indiana company.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.